LEADER 04512nam 2201261z- 450 001 9910595069203321 005 20231214133204.0 035 $a(CKB)5680000000080839 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/92104 035 $a(EXLCZ)995680000000080839 100 $a20202209d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAnticancer Inhibitors 210 $aBasel$cMDPI Books$d2022 215 $a1 electronic resource (216 p.) 311 $a3-0365-4920-X 311 $a3-0365-4919-6 330 $aThe word "cancer" is associated with at least 100 different pathologies, depending on the organ involved and the type of tumor developed. Cancer is a complex disease involving multiple pathogenetic mechanisms. Characterization of different types of cancers, which distinguishes them from healthy cells and other cancers, allows for the identification of specific targets for each individual tumor. The principle of chemotherapy is based on interference with the mechanisms that regulate the life and proliferation of cancer cells, causing their death. In recent years, there has been continuous progress in the development of therapeutic agents against cancer, which is ongoing.The Anticancer Inhibitors Special Issue focuses on new target-based anticancer agents that inhibit a specific target involved in the suppression of various types of cancer and the control of their chemoresistance.There is a collection of research and review articles on advances in drug discovery, design, and development of new inhibitor compounds with potency against various cancer types. 606 $aResearch & information: general$2bicssc 606 $aChemistry$2bicssc 610 $abreast cancer 610 $atamoxifen 610 $aLY294002 610 $asynergism 610 $aapoptosis 610 $acell cycle 610 $atea (Camellia sinensis) flowers 610 $aBTFS 610 $aA2780/CP70 ovarian cancer cells 610 $aS phase cell cycle arrest 610 $anicotinamide phosphoribosyltransferase 610 $aNAD+ biosynthesis 610 $ainhibitor 610 $aazacyclohexane 610 $aanticancer drug 610 $adrug design 610 $aenthalpy effect 610 $aNSCLC 610 $aCathepsin K 610 $acell proliferation 610 $acell migration 610 $acell invasion 610 $amTOR 610 $aisatin-hydrazones 610 $acytotoxicity 610 $aCDK2 inhibitor 610 $aATP competitive inhibitor 610 $aADME analysis 610 $areceptor tyrosine kinases 610 $aprotein-protein interactions 610 $aprotein engineering 610 $adirected evolution 610 $aangiogenesis 610 $abinding affinity 610 $aagonistic activity 610 $asaponins 610 $aphytochemicals 610 $atea (Camellia sinensis) flower 610 $aovarian cancer 610 $aautophagy 610 $aZMYND8 610 $atumorigenesis 610 $aepigenetic regulation 610 $apro-oncogenic effects 610 $atumor suppression 610 $atacrine-coumarin derivatives 610 $aDNA 610 $atopoisomerases I, II 610 $alung carcinoma cells 610 $aA549 610 $achemotherapy 610 $aprodrug 610 $adrug targeting 610 $aoverexpressed enzymes 610 $aADC 610 $aADEPT 610 $aGDEPT 610 $aLEAPT 610 $aPROTAC 610 $acyclin-dependent kinase 610 $acancer 610 $aresistance 610 $asmall molecule inhibitors 610 $aPROTACs 610 $astatins 610 $apancreatic cancer 610 $aDNA microarray 610 $apitavastatin 610 $acerivastatin 610 $asimvastatin 610 $afluvastatin 610 $aatorvastatin 610 $apravastatin 610 $aHMG-CoA reductase inhibitors 615 7$aResearch & information: general 615 7$aChemistry 700 $aFantacuzzi$b Marialuigia$4edt$01332307 702 $aAmmazzalorso$b Alessandra$4edt 702 $aFantacuzzi$b Marialuigia$4oth 702 $aAmmazzalorso$b Alessandra$4oth 906 $aBOOK 912 $a9910595069203321 996 $aAnticancer Inhibitors$93040809 997 $aUNINA